Influence of Renal and Hepatic Impairment on the Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Fluticasone Furoate and Vilanterol in Combination

Clinical Therapeutics

Volumn 34, Issue 12, 2012, Pages 2316-2332

  Allen, Ann ^a   Davis, Angela ^b   Hardes, Kelly ^a   Tombs, Lee ^c   Kempsford, Rodger ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c Synergy   (United Kingdom)

Author keywords

Fluticasone furoate; Hepatic and renal impairment; Pharmacodynamics; Pharmacokinetics; Safety; Tolerability; Vilanterol

Indexed keywords

FLUTICASONE FUROATE PLUS VILANTEROL; HYDROCORTISONE; POTASSIUM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART RATE; HUMAN; HYDROCORTISONE BLOOD LEVEL; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MORNING DOSAGE; POTASSIUM BLOOD LEVEL; RHINOPHARYNGITIS;

ADMINISTRATION, INHALATION; ADULT; AGED; ANDROSTADIENES; AREA UNDER CURVE; BENZYL ALCOHOLS; CASE-CONTROL STUDIES; CHLOROBENZENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HEPATIC INSUFFICIENCY; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX;

EID: 84870749810     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.11.001     Document Type: Article

References (38)

1. Bahadori K., Doyle-Waters M.M., Marra C., et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009, 9:24.
2. Chapman K.R., Mannino D.M., Soriano J.B., et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:188-207.
3. Global Strategy for Asthma Management and Prevention, 2011 Global Initiative for Asthma, Accessed February 16, 2012. http://www.ginasthma.org/.
4. Lopez A.D., Shibuya K., Rao C., et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006, 27:397-412.
5. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
6. Lötvall J., Bakke P.S., Bjermer L., et al. Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open 2012, 2:e000370.
7. Kempsford RD, Allen A, Bareille P, et al. The safety, tolerability, pharmacodynamics and harmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination. Presented at: European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24-28, 2011. Abstract.
8. Busse W.W., Bleecker E.R., Bateman E.D., et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2012, 67:35-41.
9. Woodcock A., Bateman E.D., Busse W.W., et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res 2011, 12:132.
10. Lötvall J., Bateman E.D., Bleecker E.R., et al. Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma. Eur Respir J 2010, 4771.
11. Kempsford RD, Norris V, Siederer SK. Vilanterol trifenatate (VI; GW642444M),a novel inhaled longacting beta2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100 μg, is well tolerated and demonstrates prolonged bronchodilation in asthmatic patients. Presented at: Annual Conference of the American Thoracic Society (ATS). New Orleans, LA, May 14-19, 2010. Abstract.
12. Kempsford RD, Norris V, Siederer SK. Vilanterol trifenatate (VI; GW642444M), a novel inhaled longacting beta2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100 μg, is well tolerated and demonstrates prolonged bronchodilation in COPD patients. Presented at: Annual Conference of the American Thoracic Society (ATS). New Orleans, LA, May 14-19, 2010. Abstract.
13. Hanania N.A., Feldman G., Zachgo W., et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial. Chest 2012, 142:119-127.
14. Hughes S.C., Shardlow P.C., Hollis F.J., et al. Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos 2008, 36:2337-2344.
15. Harrell A, Siederer S, Bal J, Kempsford R. Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man. Presented at: European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24-28, 2011. Abstract.
16. McLean A.J., Morgan D.J. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991, 21:42-69.
17. Westphal J.F., Brogard J.M. Drug administration in chronic liver disease. Drug Saf 1997, 17:47-73.
18. Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labelling Food and Drug Administration, Accessed March 12, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf.
19. Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function Committee for Medicinal Products for Human Use, European Medicines Agency, Accessed March 12, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003122.pdf.
20. Veramyst (fluticasone furoate) Nasal Spray Summary Medicinal Product Characteristics. Initial US Approval: 2007 Accessed March 12, 2012. http://us.gsk.com/products/assets/us_veramyst.pdf.
21. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 Accessed May 18, 2012. http://www.goldcopd.org/.
22. Nolin T.D., Naud J., Leblond F.A., Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008, 83:898-903.
23. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labelling Food and Drug Administration, Accessed March 7, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf.
24. Guidance on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Renal Function Committee for Medicinal Products for Human Use, European Medicines Agency, Accessed June 8, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003123.pdf.
25. Edholm M., Berglund E., Salmonson T. Regulatory aspects of pharmacokinetic profiling in special populations: a European perspective. Clin Pharmacokinet 2008, 47:693-701.
26. Thorsson L., Dahlstrom K., Edsbacker S., et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997, 43:155-161.
27. Bruni F.M., De Luca G., Venturoli V., Boner A.L. Intranasal corticosteroids and adrenal suppression. Neuroimmunomodulation 2009, 16:353-362.
28. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004, 125:2309-2321.
29. Salpeter S.R., Buckley N.S., Ormiston T.M., Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Inter Med 2006, 144:904-912.
30. Boscia J.A., Pudi K.K., Zvarich M.T., et al. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Clin Ther 2012, 34:1655-1666.e5.
31. Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects World Medical Association, Accessed March 7, 2012. http://www.wma.net/en/30publications/10policies/b3/.
32. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
33. Child C.G., Turcotte J.G. Surgery and portal hypertension. The Liver and Portal Hypertension 1964, 50-194. Saunders, Philadelphia, Pa. C.G. Child (Ed.).
34. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophageal varices. Br J Surg 1973, 60:646-649.
35. Cazzola M., Calzetta L., Matera M.G. Beta2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011, 163:4-17.
36. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Food and Drug Administration, Accessed March 7, 2012. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf.
37. Milic M., Bao X., Rizos D., Liu F., Ziegler M.G. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation. Clin Ther 2006, 28:582-590.
38. Malcolm R., Sears M.B. Adverse effects of β-agonists. J Allergy Clin Immunol 2002, 110(Suppl):S322-S328.